Kite Reports Results of Yescarta in P-II ZUMA-5 Study for Adult Patients with R/R Indolent Non-Hodgkin lymphoma
Shots:
- The P-II ZUMA-5 study involves assessing Yescarta (axicabtagene ciloleucel) in patients with r/r iNHL after at least 2L of systemic therapy. After a single infusion of Yescarta- 92% of patients responded- including 76% of patients achieving a CR @median follow-up of 17.5 mos.- results presented at ASH
- The data supports the US FDA’s acceptance of BLA and is currently under PR for r/r FL- MZL- after two or more prior lines of systemic therapy- with an anticipated PDUFA date as Mar 5- 2021
- Yescarta is the first CAR T-cell therapy to be approved by the US FDA for patients with r/r large B-cell lymphoma after two or more lines of systemic therapy
Ref: Businesswire | Image: Seek Vector Logo
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com